Racura Oncology: Lung Cancer trial targets resistance

Racura Oncology CEO & Managing Director Dr Daniel Tillett talked with Kerry Stevenson from Proactive at the the ASX Small and Mid-Cap Conference about the company’s expanding clinical pipeline and its strategy to tackle some of the biggest challenges in cancer treatment. Dr Tillett outlined three concurrent clinical programs currently underway, highlighting Racura’s diversified approach. The first program focuses on protecting the heart in patients undergoing chemotherapy using AC220, which has been progressing steadily for nearly a year. The second, the HARNESS-1 trial in lung cancer, is designed to address resistance to existing therapies by combining Racura’s drug with osimertinib, a widely used treatment. As Dr Tillett explained, “it works really well for about 18 months, and then it stops working,” referring to osimertinib, underscoring the urgent need to extend treatment effectiveness. Racura aims to prevent this resistance, potentially improving patient outcomes and survival. The company is also preparing to launch a Phase 3 trial in acute myeloid leukaemia (AML), building on earlier-stage success. This program is expected to be relatively cost-effective and streamlined due to its orphan indication status. Importantly, the HARNESS-1 trial could deliver results quickly, with early data anticipated within months. Dr Tillett noted that Racura expects to have “a good idea whether this is working or not” by the end of the year, offering investors near-term catalysts. With multiple trials progressing simultaneously, Racura is positioned to generate consistent news flow while targeting significant market opportunities in oncology. #proactiveinvestors #asx #RAC #RacuraOncology #ASXRAC #BiotechStocks #CancerResearch #LungCancer #AML #ClinicalTrials #OncologyInnovation #Biopharma #DrugDevelopment #HealthcareInvesting #ProactiveInvestors #SmallCapStocks